Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome

Uslu, Sadettin (2020) Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome. European Journal of Case Reports in Internal Medicine, 7 (6). pp. 1-3. ISSN ISSN: 2284-2594

Preview

Text 1731-Article Text-13637-1-10-20200521.pdf - Published Version Download (716kB) | Preview

Abstract

Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by many factors such as infections. CRS in patients with coronavirus disease 2019 (COVID-19) is life-threatening and can occur very rapidly after COVID-19 diagnosis. Tocilizumab (TCZ), an interleukin-6 (IL-6) inhibitor, may ameliorate the CRS associated with severe COVID-19 and thus improve clinical outcomes. We present a case of life-threatening CRS caused by COVID-19 infection successfully treated with TCZ.

Item Type:	Article
Uncontrolled Keywords:	Tocilizumab, COVID-19, cytokine release syndrome
Subjects:	600 Tecnologia - Scienze applicate 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 616 Malattie (classificare qui la Clinica medica, la medicina basata sull'evidenza, la Medicina interna, la Medicina sperimentale)
Depositing User:	Marina Spanti
Date Deposited:	14 Dec 2021 12:59
Last Modified:	14 Dec 2021 12:59
URI:	http://eprints.bice.rm.cnr.it/id/eprint/20898

Actions (login required)

View Item